Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 201

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 3
Chunk 201
---
312 shares of common stock at a purchase
price of $5.105 per share in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market LLC.

The shares were offered pursuant to a “shelf”
registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by SEC on July 18, 2024 as supplemented
by a prospectus supplement dated January 28, 2025, filed with the SEC on January 30, 2025, and accompanying base prospectus, pursuant
to Rule 424(b)(5) promulgated under the Securities Act.

In a concurrent private placement, the Company
also issued to the January 2025 Purchasers unregistered warrants (the “January 2025 Warrants”) to purchase up to an aggregate
of 408,621 shares of common stock at an exercise price of $3.855 per share. The January 2025 Warrants are exercisable upon issuance and
expire twenty-four months from the date of issuance.

Any holder will not have the right to exercise
any portion of the January 2025 Warrants if the holder (together with its affiliates) would beneficially own more than 4.99% (or, upon
the election of the holder, 9.99%) of the number of shares of the common stock outstanding immediately after giving effect to the exercise,
as such percentage ownership is determined in accordance with the terms of the warrants. However, any holder may increase or decrease
such percentage, provided that any increase will not be effective until the 61st day after such election.

The exercise price of the January 2025 Warrants
is subject to customary adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications
or similar events affecting the common stock and also upon any distributions of assets, including cash, stock or other property to the
stockholders of the Company.

The issuance of the January 2025 Warrants pursuant
to the January 2025 Securities Purchase Agreement and issuance of the January 2025 Placement Agent Warrants, as defined below, and the
shares of common stock issuable thereunder were made pursuant to the exemption from the registration requirements under the Securities
Act, available to the Company under Section 4(a)(2) promulgated thereunder and Rule 506 of Regulation D promulgated under the Securities
Act due to the fact that the offering of the January